Moderna's Cancer Vaccine Succeeds in Phase 3, Shares Double

The personalized mRNA cancer vaccine candidate developed jointly by Moderna and Merck has met its primary endpoints in a Phase 3 clinical trial involving melanoma patients. The experimental treatment demonstrated efficacy in reducing the risk of cancer recurrence and metastasis after surgery. In the study, the vaccine was administered in combination with Merck's immunotherapy drug Keytruda. These results are considered a significant milestone in the field of personalized mRNA cancer therapies. The treatment is specifically designed based on each patient's tumor profile and aims to train the immune system to target cancer cells. Following the development, Moderna's stock price surged by more than 100%, attracting investor attention. This rally is interpreted as a strong market response to the company's potential in the cancer vaccine space. Experts note that this success indicates mRNA technology could revolutionize not only infectious diseases but also oncology. However, regulatory approval processes must be completed before the treatment can be used in broader patient populations. This is not investment advice.